Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Venlafaxine + lisdexamfetamine
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Venlafaxine + lisdexamfetamine is a combination of two pharmaceutical agents used primarily in psychiatric and neurobehavioral disorders. Venlafaxine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that increases synaptic concentrations of serotonin and norepinephrine by inhibiting their reuptake at the presynaptic terminal. It also weakly inhibits dopamine reuptake. Lisdexamfetamine is an inactive prodrug that is converted in the body to dextroamphetamine, which acts as a central nervous system stimulant by increasing the release of monoamines (dopamine and norepinephrine) via Trace amine-associated receptor 1 (TAAR1) agonism and vesicular monoamine transporter 2 inhibition. This combination may be considered for treatment-resistant depression or comorbid attention-deficit hyperactivity disorder (ADHD) with mood disorders; however, coadministration requires careful monitoring due to potential additive side effects such as increased blood pressure, heart rate, anxiety, or jitteriness[1][3][8][6].
- Brand names
- VyvanseEffexorVensirVencarmVenlalixEfexorVenlablue
- Other names
- venlafaxinelisdexamfetamine dimesylate
02
Targets
DAT (Dopamine plasma membrane transport protein)VMAT2 (Vesicular monoamine transporter 2)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)TAAR1 (Trace amine-associated receptor 1)
Beyond the preview
Go deeper on Venlafaxine + lisdexamfetamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Venlafaxine + lisdexamfetamine.